- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01182051
A Study of Family-based Cognitive-behavioral Therapy for Chronic Pediatric Headache and Anxiety
A Pilot Study of Family-based Cognitive-behavioral Therapy for Treating Chronic Pediatric Headache/Migraine and Comorbid Anxiety
The primary aim of this proposal is to refine the intervention under investigation (i.e., family-based CBT) and evaluate the feasibility and acceptability of the intervention and methods (e.g., recruitment, assessments).
The secondary aim of this proposal is to compare the relative efficacy of an 8 session family-based cognitive-behavioral therapy (CBT) to Relaxation Training (RT) for reducing anxiety and chronic headaches in youth (N = 30) ages 7-17 years. It is hypothesized that CBT will result in greater reductions in both anxiety and headache frequency and severity compared to RT.
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Johns Hopkins
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- To determine eligibility, youth will complete an evaluation consisting of clinical interviews, self-, and parent-report measures.
To be included in the study, all children must:
- have a current diagnosis of chronic daily headache, tension-type headache, and/or migraine headache
- obtain a total score on the Screen for Child Anxiety Related Disorders (SCARED) in the clinical range (i.e., > 20)
- be between 7 and 17 years old
- have a parent/guardian who gives consent and agrees to participate
- be English speaking
- not currently participating in other psychosocial treatments specifically directed at reducing head pain or anxiety.
- For youth receiving prophylactic medication, it is preferable that they remain on a stable dose and agree to avoid medication changes while enrolled in the study. Thus, all participants will be permitted to continue with their prescribed medical/neurological treatment, however the use of medications (both prophylactic and over-the-counter analgesics) will be closely monitored.
Exclusion Criteria:
- Youth will be excluded from the study if they have a medical or psychiatric condition contraindicating study treatment or warranting an alternative intervention (e.g., suicidality, depression).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Cognitive behavioral therapy
Key treatment ingredients in CBT include psychoeducation, trigger identification, progressive muscle relaxation training, cognitive restructuring, problem solving, in vivo exposure, and relapse prevention (see Appendix I for an outline of the treatment manual).
|
8 weeks of CBT or relaxation training.
|
|
ACTIVE_COMPARATOR: Relaxation Training
RT will consist of progressive muscle relaxation training, diaphragmatic breathing, and thermal biofeedback.
|
8 weeks of CBT or relaxation training.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Daily Headache and Anxiety Diary
Time Frame: Daily for three months
|
Youth and parents will complete a daily headache and anxiety diary to track the frequency and severity of headaches and anxiety symptoms.
In addition, the diary will assess medication use, missed school/activities, as well as antecedents and consequences.
|
Daily for three months
|
|
Pediatric Anxiety Rating Scale (PARS)
Time Frame: 2 months
|
The Pediatric Anxiety Rating Scale (PARS) will be completed by an independent evaluator to assess the severity of current (within the past week) anxiety symptoms in youth.
The instrument consists of two sections.
The first section contains a 50-item anxiety symptoms checklist.
The second section assesses the severity and impairment of these symptoms.
A total score is computed by summing the severity items.
The measure has acceptable internal consistency, reliability, and convergent/divergent validity.
|
2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pediatric Migraine Disability Assessment (PedMIDAS)
Time Frame: 2 months
|
The Pediatric Migraine Disability Assessment (PedMIDAS) is used to assess migraine disability across multiple domains of functioning including school, home, social, and recreational.
The measure consists of 6 items measuring the number of days in which activities were missed as a result of headache/migraine.
The measure yields a total score by summing items.
Total scores correspond to one of four "disability grades:" 0-10 = little to no disability, 11-30 = mild disability, 31-50 = moderate disability, and >50 = severe disability.
|
2 months
|
|
Pediatric Migraine Disability Assessment (PedMIDAS)
Time Frame: 3 months
|
The Pediatric Migraine Disability Assessment (PedMIDAS) is used to assess migraine disability across multiple domains of functioning including school, home, social, and recreational.
The measure consists of 6 items measuring the number of days in which activities were missed as a result of headache/migraine.
The measure yields a total score by summing items.
Total scores correspond to one of four "disability grades:" 0-10 = little to no disability, 11-30 = mild disability, 31-50 = moderate disability, and >50 = severe disability.
|
3 months
|
|
Pediatric Anxiety Rating Scale (PARS)
Time Frame: 3 months
|
The Pediatric Anxiety Rating Scale (PARS) will be completed by an independent evaluator to assess the severity of current (within the past week) anxiety symptoms in youth.
The instrument consists of two sections.
The first section contains a 50-item anxiety symptoms checklist.
The second section assesses the severity and impairment of these symptoms.
A total score is computed by summing the severity items.
The measure has acceptable internal consistency, reliability, and convergent/divergent validity.
|
3 months
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NA-00019444
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.